Barclays Calls Helus Pharma’s Friday Selloff a Buying Opportunity After $35 Initiation
Helus Pharma sold off Friday after Barclays’ $35 initiation. The bank says APPROACH data are not the sole basis for its rating.
/ 6 items
#HELP↓
Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
Helus Pharma's HLP004 Phase 2: Small Study, Promising but Limited Signals
Helus Pharma's (Cybin/HELP) HLP004 Phase 2 trial shows potential adjunctive benefits in GAD but small size, 39% remission, no approval, injection format, and Phase 3 years away limit broad claims.
One DMT Dose Relieved Depression for Up to 6 Months
A new clinical trial published in Nature Medicine found that one dose of DMT (SPL026) significantly reduced depression symptoms in two weeks — with effects lasting up to six months for some patients.